Clinical trials: Myasthenia Gravis (MG), open to volunteers
Generalized Myasthenia Gravis, Anti-AChR Antibody Positive
Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
The primary objective of the study is to evaluate the effectiveness of Ravulizumab in improving MG-ADL in an early-stage AChR+ gMG population.
- Trial name
- NCT06967480
- Testing
- Ravulizumab
- Where
- 23 sites in Italy
- Volunteers
- 40 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Generalized Myasthenia Gravis (gMG)
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
RESET-MG: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Participants with Generalized Myasthenia Gravis
- Trial name
- NCT06359041
- Testing
- CABA-201
- Where
- 17 sites in United States
- Volunteers
- 24 people
- Sponsor
- Cabaletta Bio
Myasthenia Gravis, MG
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis.
- Conditions
- Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis
- Trial name
- NCT07294170
- Testing
- Efgartigimod IV, Empasiprubart IV, Efgartigimod PH20 SC PFS
- Where
- 37 sites in United States, Belgium and 6 more
- Volunteers
- 70 people
- Sponsor
- argenx
Myasthenia Gravis
Vitaccess Real MG Registry
Vitaccess Real MG (VRMG) is a patient registry designed to capture longitudinal observational data on myasthenia gravis (MG), its treatment, and impact on symptoms, daily activities, and quality of life (QoL).
- Trial name
- VRMG (NCT06064461)
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 600 people
- Sponsor
- Vitaccess Ltd
Myasthenia Gravis (MG)
Talquetamab in Patients With Refractory Generalized Myasthenia Gravis
Myasthenia Gravis (MG) is a chronic autoimmune disease mediated by pathogenic antibodies. Approximately 10%-15% of patients present with refractory status, defined as having an inadequate response to existing therapies or an…
- Trial name
- NCT07499323
- Testing
- Talquetamab
- Volunteers
- 2 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Myasthenia Gravis (MG), Myasthenia Gravis Associated With Thymoma
Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia Gravis
The goal of this observational study is to investigate the clinical, immunological, and neuromuscular features associated with the development and progression of myasthenia gravis (MG) in adult patients with thymic abnormalities…
- Conditions
- Myasthenia Gravis (MG), Myasthenia Gravis Associated With Thymoma, Thymoma
- Trial name
- TAILOR-MG (NCT07571525)
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- IRCCS San Raffaele
Myasthenia Gravis
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
The primary purpose of this study is to evaluate the efficacy of ublituximab in adult participants with MG responding to treatment with efgartigimod.
- Trial name
- NCT07673744
- Testing
- Ublituximab
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- TG Therapeutics, Inc.
Generalized Myasthenia Gravis (gMG)
Zilucoplan for Severe gMG Exacerbations
This is an open-label, multicenter, interventional phase 3b study in participants with AChR+ gMG and severe exacerbation that require hospitalization. Patients will receive subcutaneous zilucoplan injections daily for 12 weeks.
- Trial name
- NCT07215949
- Testing
- Zilucoplan®
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Miriam Freimer
Multiple Sclerosis (MS), Myasthenia Gravis (MG)
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard…
- Conditions
- Multiple Sclerosis (MS), Myasthenia Gravis (MG), Neuromyelitis Optica Spectrum Disorder, Systemic Lupus Erythematosus
- Trial name
- NCT07676266
- Testing
- CD20/BCMA-directed CAR-T cells Autologous 2nd generation
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Myasthenia Gravis (MG)
Feasibility of Remote Monitoring of Patients With Myasthenia Gravis
Myasthenia gravis is an autoimmune neuromuscular disorder characterized by fluctuating weakness, which can worsen suddenly without a clear predictor.
- Trial name
- ROME-MG (NCT07787247)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- George Washington University
Myasthenia Gravis (MG)
Sexual and Urinary Dysfunctions in Generalized Myasthenia
Myasthenia gravis is an autoimmune disease caused by specific autoantibodies that disrupt the function of the neuromuscular junction.
- Trial name
- MYAOUS (NCT07677852)
- Testing
- No intervetion
- Where
- 2 sites in France
- Volunteers
- 150 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN)
A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
This is an investigator-initiated, open-label, single-arm, dose-escalation and dose-expansion study to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of MTM-H-001 in adult participants with B-cell-related…
- Conditions
- Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN), Multiple Sclerosis, Myasthenia Gravis (MG)
- Trial name
- ArchAid-002 (NCT07593911)
- Testing
- MTM-H-001 Injection
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Beijing GoBroad Hospital
Myasthenia Gravis, MuSK MG
MuSK Myasthenia 1000 Study
The MuSK myasthenia gravis 1000 study seeks to collect saliva samples from 1000 subjects with laboratory confirmed diagnosis of MuSK myasthenia to identify genetic variations associated with MuSK MG.
- Conditions
- Myasthenia Gravis, MuSK MG, MuSK Myasthenia Gravis
- Trial name
- MuSK 1000 (NCT06259071)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- George Washington University
Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD)
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
This study is an open-label, exploratory, prospective clinical trial with dose escalation(according to "3+3" design), to evaluate the safety and tolerability of QH103(Universal CD19 CAR-γδT Cell Injection)in the treatment of…
- Conditions
- Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), Autoimmune Encephalitis (AE), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Trial name
- NCT07526493
- Testing
- Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Tongji Hospital
Myasthenia Gravis (MG)
Ripertamab for the Treatment of Myasthenia Gravis
The goal of this clinical trial is to learn if ripertamab works to treat myasthenia gravis. It will also learn about the safety of ripertamab.
- Trial name
- RIPERT-MG (NCT07372807)
- Testing
- ripertamab
- Volunteers
- 20 people
- Sponsor
- Zhongming Qiu
Myasthenia Gravis (MG), Myasthenia Gravis, Generalized
AXIS MG Patient Registry
The goal of the AXIS Autoimmune Neurology Registry is to learn about the experiences of adults living with autoimmune neurological disorders, starting with myasthenia gravis (MG), over time.
- Conditions
- Myasthenia Gravis (MG), Myasthenia Gravis, Generalized, Myasthenia Gravis, Ocular, Myasthenia Gravis Crisis
- Trial name
- AXIS (NCT07761026)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Autoimmune Neurology Alliance
Myasthaenia Gravis
Blinatumomab in Refractory Myasthenia Gravis (BLINA-MG)
The goal of this clinical trial is to evaluating the efficacy and safety of Blinatumomab in the treatment of refractory myasthenia gravis and exploring the immunological mechanisms of Blinatumomab therapy in refractory myasthenia…
- Trial name
- BLINA-MG (NCT06684184)
- Testing
- Blinatumomab
- Volunteers
- 10 people
- Sponsor
- Zhongming Qiu
Myasthenia Gravis
PPDTM CorEvitasTM Myasthenia Gravis (MG) Drug Safety and Effectiveness Registry
The design is a prospective, observational (non-interventional) registry for subjects with myasthenia gravis under the care of a neurology provider.
- Trial name
- NCT07217509
- Where
- United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- CorEvitas
Myasthenia Gravis
The EXPLORE MG Registry for Myasthenia Gravis
The purpose of this study is to create a Yale University Department of Neurology Myasthenia Gravis (MG) registry that will be used for current and future research projects involving the study of Myasthenia Gravis.
- Trial name
- NCT03792659
- Testing
- Blood Sample Draw
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- Yale University
Myasthenia Gravis, Generalized
Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.
- Trial name
- MG-ARCADIA (NCT06909253)
- Testing
- Ravulizumab
- Where
- 11 sites in Poland
- Volunteers
- 50 people
- Sponsor
- AstraZeneca